0.939 USD
+0.1 (+11.53%)
0.92 USD
-0.02 (-2.02%)
We assign a fundamental rating of 3 out of 10 to ENSC. ENSC was compared to 525 industry peers in the Biotechnology industry. ENSC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ENSC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- ENSC had negative earnings in the past year.
- In the past year ENSC has reported a negative cash flow from operations.
- ENSC had negative earnings in 4 of the past 5 years.
- In the past 5 years ENSC always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -345.10%, ENSC is doing worse than 92.19% of the companies in the same industry.
- ENSC has a worse Return On Equity (-911.79%) than 78.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -345.1% | ||
| ROE | -911.79% | ||
| ROIC | N/A |
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ENSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ENSC has more shares outstanding than it did 1 year ago.
- ENSC has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for ENSC has been reduced compared to a year ago.
2.2 Solvency
- ENSC has an Altman-Z score of -69.21. This is a bad value and indicates that ENSC is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -69.21, ENSC is not doing good in the industry: 92.57% of the companies in the same industry are doing better.
- ENSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -69.21 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- ENSC has a Current Ratio of 1.27. This is a normal value and indicates that ENSC is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.27, ENSC is doing worse than 83.43% of the companies in the same industry.
- A Quick Ratio of 1.27 indicates that ENSC should not have too much problems paying its short term obligations.
- ENSC's Quick ratio of 1.27 is on the low side compared to the rest of the industry. ENSC is outperformed by 82.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 79.48% over the past year.
- The Revenue has been growing slightly by 1.51% in the past year.
- ENSC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.86% yearly.
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-222.86%
Revenue 1Y (TTM)1.51%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%-85.58%
3.2 Future
- The Earnings Per Share is expected to grow by 41.95% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 176.07% on average over the next years. This is a very strong growth
EPS Next Y64.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-10.84%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 4.72, the valuation of ENSC can be described as very cheap.
- Based on the Price/Forward Earnings ratio, ENSC is valued cheaper than 99.43% of the companies in the same industry.
- ENSC's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.72 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ENSC's earnings are expected to grow with 41.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.95%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for ENSC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.939
+0.1 (+11.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners7.48%
Inst Owner Change0%
Ins Owners0.29%
Ins Owner Change0%
Market Cap3.32M
Revenue(TTM)4.49M
Net Income(TTM)-10.97M
Analysts82.86
Price Target25.73 (2640.15%)
Short Float %4.85%
Short Ratio0.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.92%
Min EPS beat(2)-46.21%
Max EPS beat(2)34.36%
EPS beat(4)2
Avg EPS beat(4)9.75%
Min EPS beat(4)-46.21%
Max EPS beat(4)54.8%
EPS beat(8)5
Avg EPS beat(8)24.08%
EPS beat(12)9
Avg EPS beat(12)31.22%
EPS beat(16)11
Avg EPS beat(16)-101.82%
Revenue beat(2)1
Avg Revenue beat(2)37.92%
Min Revenue beat(2)-30.95%
Max Revenue beat(2)106.79%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.81%
PT rev (3m)-3.81%
EPS NQ rev (1m)-34.76%
EPS NQ rev (3m)-86.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.5%
Revenue NQ rev (1m)100%
Revenue NQ rev (3m)-28.57%
Revenue NY rev (1m)100%
Revenue NY rev (3m)34.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.72 | ||
| P/S | 0.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.76 | ||
| P/tB | 2.76 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.37
EYN/A
EPS(NY)0.2
Fwd EY21.18%
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS1.27
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -345.1% | ||
| ROE | -911.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | -69.21 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-222.86%
EPS Next Y64.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.51%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%-85.58%
Revenue Next Year-10.84%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
EBIT growth 1Y-74.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.36%
EBIT Next 3Y51.15%
EBIT Next 5YN/A
FCF growth 1Y41.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.63%
OCF growth 3YN/A
OCF growth 5YN/A
ENSYSCE BIOSCIENCES INC / ENSC FAQ
Can you provide the ChartMill fundamental rating for ENSYSCE BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 3 / 10 to ENSC.
What is the valuation status for ENSC stock?
ChartMill assigns a valuation rating of 4 / 10 to ENSYSCE BIOSCIENCES INC (ENSC). This can be considered as Fairly Valued.
Can you provide the profitability details for ENSYSCE BIOSCIENCES INC?
ENSYSCE BIOSCIENCES INC (ENSC) has a profitability rating of 0 / 10.
How financially healthy is ENSYSCE BIOSCIENCES INC?
The financial health rating of ENSYSCE BIOSCIENCES INC (ENSC) is 5 / 10.